Just been scrolling through some clinical-stage biotech plays and realized there's actually solid opportunity in the sub-$10 space if you've got the risk appetite for it. These aren't your blue-chip pharma bets, but the upside potential on some of these is genuinely interesting.

Starting with Actinium Pharmaceuticals (ATNM) - they're working on targeted radiotherapies for cancer patients with serious unmet needs. Their Phase 3 candidate targets elderly patients with relapsed leukemia. Wall Street's pretty bullish here, with analysts calling it a strong buy and average targets around $30.50. We're talking 239% upside on average, with some targets hitting $50. Yeah, they're basically pre-revenue right now, but projections show $72.82 million in sales coming by 2025.

Then there's Outlook Therapeutics (OTLK) - focused on monoclonal antibodies for eye diseases. Their lead candidate ONS-5010 is in Phase 3 trials for wet age-related macular degeneration. The Street's equally enthusiastic here with unanimous strong buy ratings and average price targets at $40.20. That's 362% growth potential. Revenue's starting to show up too - analysts expect $240k to $1.43 million this year, then jumping to $13.09 million next year.

Recursion Pharmaceuticals (RXRX) is interesting because they're actually generating revenue already. They're combining tech innovation with drug discovery, currently in Phase 2 trials for cerebral cavernous malformation treatment. Analysts rate it a moderate buy with $17 average targets. Revenue's expected to hit $56.16 million this year, growing 57.5% to $88.43 million next year.

Ocular Therapeutix (OCUL) is another eye-disease play with an axitinib implant in Phase 3 trials for macular degeneration. Consensus strong buy with $16.33 average targets and potential upside to $24. They're actually profitable-adjacent territory - revenue expected around $68.34 million with 16.9% YOY growth.

Marinus (MRNS) focuses on rare genetic epilepsies. Their main product Ztalmy is already generating revenue - $30.99 million last year with projections hitting $40.53 million this year and $66.62 million by 2025. Analysts see 163% upside potential with average targets at $19.78.

Fulcrum Therapeutics (FULC) has a small-molecule candidate in Phase 3 trials for muscular dystrophy. They're clinical-stage but with serious 2025 revenue projections of $13.34 million jumping to potentially $42.88 million. Consensus strong buy with $13.29 average targets.

Finally, CorMedix (CRMD) is developing DefenCath for catheter-related infections. Riskier profile but unanimous strong buy ratings with $12.67 average targets implying 117% upside. Revenue's projected to explode from $25.16 million this year to $81.93 million next year.

Look, these best medical stocks under $10 are definitely speculative - clinical trials can go sideways on anybody. But if you're comfortable with biotech volatility, the risk-reward on some of these candidates is worth monitoring. The analyst consensus across the board is pretty strong, and several have real revenue inflection points coming. Just do your homework on the specific clinical data before jumping in.